Phenylketonuria: Optimizing Therapeutic Efficacy
|
|
- Fay Dennis
- 5 years ago
- Views:
Transcription
1 Phenylketonuria: Optimizing Therapeutic Efficacy Expanded Reference List Abadie V, Berthelot J, Feillet F, et al. Management of phenylketonuria and hyperphenylalaninemia: the French guidelines. Arch Pediatr. 2005;12(5): Acosta PB. Nutrition studies in treated infants and children with phenylketonuria: vitamins, minerals, trace elements. Eur J Pediatr. 1996;155(suppl 1):S136-S139. Acosta PB, Yannicelli S. Plasma micronutrient concentrations in infants undergoing therapy for phenylketonuria. Biol Trace Elem Res. 1999;67(1): Acosta PB, Yannicelli S, Parton P, et al. Nutrient intake and growth of infants with phenylketonuria undergoing therapy. J Pediatr Gastroenterol Nutr. 1998;27(3): Acosta PB. Ross Metabolic Formula System: Nutrition Support Protocols, 4 th Edition. Columbus, OH: Ross Laboratories; Available at Accessed March 8, Acosta PB. Protocol for Nutrition Support of Maternal PKU. Columbus, OH: Ross Laboratories; American Academy of Pediatrics. Policy statement: breastfeeding and the use of human milk. Pediatrics. 2005;115(2): Asia Pacific J Clin Nutrition. Available at Accessed March Bilginsoy C, Waitzman N, Leonard CO, Ernst SL. Living with phenylketonuria: perspectives of patients and their families. J Inherit Metab Dis. 2005;28(5): Bodoy S, Martin L, Zorzano A, Palacin M, Estevez R, Bertran J. Identification of LAT 4, a novel amino acid transporter with system L activity. J Biol Chem. 2005;280(12): Burgard P, Bremer HJ, Bührdel P, et al. Rationale for the German recommendations for phenylalanine level control in phenylketonuria Eur J Pediatr. 1999;158(1): Burton BK, Grange DK, Milanowski A, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6Rtetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis. 2007;(5): Burton BK, Santwana K, Kirkpatrick P. Fresh from the pipeline: sapropterin. Nature Rev. 2008;7: Camfield CS, Joseph M, Hurley T, Campbell K, Sanderson S, Camfield PR. Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care. J Pediatr. 2004;145(1): Page 1
2 Channon S, Goodman G, Zlotowitz S, Mockler C, Lee PJ. Effects of dietary management of phenylketonuria on long-term cognitive outcome. Arch Dis Child. 2007;92(3): Christine M. Trahms Program for Phenylketonuria. University of Washington at Seattle. Available at Accessed March 7, Christine M. Trahms Program for Phenylketonuria. University of Washington at Seattle. Aim for healthy choices. Available at Accessed March 7, Clinicaltrials.gov. NCT NCT NCT NCT NCT NCT NCT NCT NCT NCT NCT NCT NCT NCT NCT Accessed February 23, Erlandsen H, Pey AL, Gámez A, et al. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci U S A. 2004;101(48): Feldmann R, Denecke J, Grenzebach M, Weglage J. Frontal lobe-dependent functions in treated phenylketonuria: blood phenylalanine concentrations and long-term deficits in adolescents and young adults. J Inherit Metab Dis. 2005;28(4): Gambol PJ. Maternal phenylketonuria syndrome and case management implications. J Pediatr Nurs. 2007;22(2): Gentile JK, Fickie MR, Waisbren S. Phenylketonuria: outcomes and treatment. Pediatric Health. 2008;2(2) Gentile JK, Ten Hoedt AE, Bosch AM. Psychosocial aspects of PKU: hidden disabilities--a review. Mol Genet Metab. 2010;99(suppl 1):S64-S67. Giovannini M, Verduci E, Salvatici E, Fiori L, Riva E. Phenylketonuria: dietary and therapeutic challenges. J Inherit Metab Dis. 2007;30(2): Güttler F, Azen C, Guldberg P, et al. Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome. Pediatrics. 2003;112(6 Pt 2): Hoeks MP, den Heijer M, Janssen MC. Adult issues in phenylketonuria. Neth J Med. 2009;67(1):2-7. Huijbregts SC, de Sonneville LM, Licht R, van Spronsen FJ, Verkerk PH, Sergeant JA. Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations. Neuropsychologia. 2002;40(1):7-15. Kanufre VC, Starling AL, Leão E. Breastfeeding in the treatment of children with phenylketonuria. J Pediatr (Rio J). 2007;83(5): Kaye CI and the Committee on Genetics. Newborn screening fact sheets. Pediatrics. 2006;118;e934-e963. Page 2
3 Kindt E, Halvorsen S. The need of essential amino acids in children. Am J Clin Nutrition. 1980;33: Koch R, Friedman E, Azen C, et al. The international collaborative study of maternal phenylketonuria: status report Eur J Pediatr. 2000;159(suppl 2):S156-S160. Lenke RR, Levy HL. Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies. N Engl J Med.1980:303(21): Lee P, Treacy EP, Crombez E, et al; Sapropterin Research Group. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet A. 2008;146A(22): Leuzzi V, Pansini M, Sechi E, et al. Executive function impairment in early-treated PKU subjects with normal mental development. J Inherit Metab Dis. 2004;27(2): Levy HL, Waisbren SE. PKU in adolescents: rationale and psychosocial factors in diet continuation. Acta Paediatr Suppl. 1994;407: Levy HL, Milanowski A, Chakrapani A, et al; Sapropterin Research Group. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet. 2007;370(9586): Longo N, Harding CO, Burton BK, et al. A phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of single, subcutaneous doses of ravpal-peg in subjects with phenylketonuria. Presented at European Society of Phenylketonuria and Allied Disorders Treated as Phenylketonuria. Belek, Turkey, June Longo N, Ernst SL, Viau K, Knuth M, Baily C, Botto L. Enzyme substitution therapy and other new treatments for phenylketonuria. Presented at 2 nd European Phenylketonuria Group EPG Advances and Challenges in PKU. Munich, Germany, January MacLeod EL, Gleason ST, van Calcar SC, Ney DM. Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes. Mol Genet Metab. 2009;98(4): Maillot F, Lilburn M, Baudin J, Morley DW, Lee PJ. Factors influencing outcomes in the offspring of mothers with phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine. Am J Clin Nutr. 2008;88(3): Matalon KM, Acosta PB, Azen C. Role of nutrition in pregnancy with phenyletonuria and birth defects. Pediatrics. 2003;112: Matalon R, Michals-Matalon K, Bhatia G. et al. Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis. 2006;29(6): Matalon R, Michals-Matalon K, Bhatia G, et al. Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J Inherit Metab Dis. 2007;(2): McCabe L, Ernest AE, Neifert MR, et al. The management of breast feeding among infants with phenylketonuria. J Inherit Metab Dis.1989:12(4): Page 3
4 Medical Research Council Working Party on Phenylketonuria. Recommendations on the dietary management of phenylketonuria. Arch Dis Child. 1993;68(3): Millner BN. Insurance coverage of special foods needed in the treatment of phenylketonuria. Public Health Rep. 1993;108(1): Moyle JJ, Fox AM, Arthur M, Bynevelt M, Burnett JR. Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU. Neuropsychol Rev. 2007;17(2): Munck BG, Munck LK. Phenylalanine transport in rabbit small intestine. J Physiol. 1994;480: National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management, October 16-18, Pediatrics. 2001;108(4) Pietz J, Fätkenheuer B, Burgard P, Armbruster M, Esser G, Schmidt H. Psychiatric disorders in adult patients with early-treated phenylketonuria. Pediatrics. 1997;99(3): Pietz J, Kreis R, Rupp A, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest. 1999;103(8): Ruch T, Kerr D. Decreased essential amino acid requirements without catabolism in phenylketonuria and maple syrup urine disease. Am J Clin Nutrition.1982;35(2): Rylance G. Outcome of early detected and early treated phenylketonuria patients. Postgrad Med J. 1989;65(supp 2):S7-S9. Sarkissian CN, Gámez A, Wang L, et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc Natl Acad Sci U S A. 2008;105(52): Sinai LN, Kim SC, Casey R, Pinto-Martin JA. Phenylketonuria screening: effect of early newborn discharge. Pediatrics. 1995;96(4 Pt 1): Subcommittee on the Tenth Edition of the Recommended Dietary Allowances, Food and Nutrition Board, Commission on Life Sciences, National Research Council. Recommended Dietary Allowances: 10 th Edition. Washington, DC: The National Academies Press; Trefz FK, Burton BK, Longo N, et al; Sapropterin Study Group. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr. 2009;154(5): van Rijn M, Bekhof J, Dijkstra T, Smit PG, Moddermam P, van Spronsen FJ. A different approach to breast-feeding of the infant with phenylketonuria. Eur J Pediatr. 2003;162(5): Van Spronsen FJ, de Groot, MJ, Joeksma M, Reijngoud, D-J, van Rijn, M. Large neutral amino acids in the treatment of PKU: from theory to practice. J Inherit Metab Dis. 2010;33(6): USDA National Nutrient Database for Standard Reference. Accessed March 1, Waisbren SE, Zaff J. Personality disorder in young women with treated phenylketonuria. J Inherit Metab Dis. 1994;17(5): Page 4
5 Waisbren SE, Noel K, Fahrbach K, et al. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab. 2007;92(1-2): Waisbren S, White DA. Screening for cognitive and social-emotional problems in individuals with PKU: tools for use in the metabolic clinic. Mol Genet Metab. 2010;99(suppl 1):S96-S99. Weglage J, Fünders B, Wilken B, et al. Psychological and social findings in adolescents with phenylketonuria. Eur J Pediatr. 1992;151(7): White DA, Nortz MJ, Mandernach T, Huntington K, Steiner RD. Age-related working memory impairments in children with prefrontal dysfunction associated with phenylketonuria. J Int Neuropsychol Soc. 2002;8(1):1-11. Page 5
Molecular Genetics and Metabolism
Molecular Genetics and Metabolism 101 (2010) 110 114 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Sapropterin therapy increases
More informationNutritional factors affecting serum phenylalanine concentration during pregnancy for identical twin mothers with phenylketonuria
Nutritional factors affecting serum phenylalanine concentration during pregnancy for identical twin mothers with phenylketonuria By: C. Fox, J. Marquis, D.E. Kipp This is the accepted version of the following
More informationCommittee Approval Date: August 15, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru152 Topic: Kuvan, sapropterin Date of Origin: March 18, 2008 Committee Approval Date: August 15, 2014 Next Review Date: September 2015 Effective Date: October 1,
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: van Spronsen FJ, van Wegberg AMJ, Ahring K,
More informationNEUROCOGNITIVE, OUTCOMES IN PKU: IT S TIME TO RAISE THE BAR
NEUROCOGNITIVE, OUTCOMES IN : IT S TIME TO RAISE THE BAR KEY POINTS 1. High Phenylalanine (Phe) levels harm the brain.. Traditional therapies do not completely protect individuals with. 3. New approaches
More informationClinical Commissioning Policy: Sapropterin for Phenylketonuria (all ages) NHS England Reference: P
Clinical Commissioning Policy: Sapropterin for Phenylketonuria (all ages) NHS England Reference: 1713P 1 NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning
More informationRevision Log. See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kuvan) Reference Number: CP. PHAR.43 Effective Date: 02.01.10 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationChallenges and Pitfalls in the Management of Phenylketonuria
Challenges and Pitfalls in the Management of Phenylketonuria AUTHORS: François Feillet, MD, a Francjan J. van Spronsen, PhD, b Anita MacDonald, PhD, c Friedrich K. Trefz, MD, d Mübeccel Demirkol, MD, e
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 99 (2010) S90 S95 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Future treatment strategies
More information9 7) 843 (300) 888 (323) (257) 3 (240) 0001). 6 18/41 (44%) (95% CI
Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study Harvey
More informationChapter 1: What is PKU?
Chapter 1: What is PKU? A Parent's Perspective "If our child with PKU had been our first instead of our third, or if we had wanted more children after we had her, we would have done so, even knowing the
More information4. FJ van Spronsen, GM Enns. Future treatment strategies in phenylketonuria. Molecular Genetics and Metabolism 99 (2010): S90 S95.
References 1. National Institutes of Health Consensus Development Panel (2001) National Institutes of Health Consensus Development Conference Statement. Phenylketonuria (PKU): Screening and Management,
More informationCorrelation of Age-Specific Phenylalanine Levels on Intellectual Outcome in Patients with Phenylketonuria
Utah State University DigitalCommons@USU All Graduate Theses and Dissertations Graduate Studies 5-2010 Correlation of Age-Specific Phenylalanine Levels on Intellectual Outcome in Patients with Phenylketonuria
More informationPhenylketonuria (PKU) is an inherited metabolic disorder involving a group of genetic mutations that reduce the ability
Tetrahydrobiopterin Therapy for Phenylketonuria in Infants and Young Children Barbara K. Burton, MD, Darius J. Adams, MD, Dorothy K. Grange, MD, John I. Malone, MD, Elaina Jurecki, MS, RD, Heather Bausell,
More informationPhenylketonuria: No Specific Frontal Lobe-Dependent Neuropsychological Deficits of Early-Treated Patients in Comparison with Diabetics
0031-3998/02/5106-0761 PEDIATRIC RESEARCH Vol. 51, No. 6, 2002 Copyright 2002 International Pediatric Research Foundation, Inc. Printed in U.S.A. Phenylketonuria: No Specific Frontal Lobe-Dependent Neuropsychological
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 101 (2010) 99 109 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Minireview Suboptimal outcomes
More informationClinical Commissioning Policy: Sapropterin (Kuvan ) For Phenylketonuria: Use In Pregnancy. December Reference : NHSCB/E6/a
Clinical Commissioning Policy: Sapropterin (Kuvan ) For Phenylketonuria: Use In Pregnancy December 2012 Reference : NHSCB/E6/a NHS Commissioning Board Clinical Commissioning Policy: Sapropterin (Kuvan
More informationPKU, KUVAN, and You PKU treatment and support for adults and young adults
PKU, KUVAN, and You PKU treatment and support for adults and young adults An educational brochure brought to you by BioMarin Pharmaceutical Inc. Phe control it s a lifelong goal! Most young people with
More informationPhenylketonuria (PKU), an autosomal recessive
Management of Phenylketonuria for Optimal Outcome: A Review of Guidelines for Phenylketonuria Management and a Report of Surveys of Parents, Patients, and Clinic Directors Rebecca Wappner, MD*; Sechin
More information2015 PKU Patient Survey Results. National PKU Alliance PO Box 501, Tomahawk, WI
2015 PKU Patient Survey Results National PKU Alliance PO Box 501, Tomahawk, WI 54487 www.npkua.org www.adultswithpku.org The NPKUA Patient Survey demonstrates that strict dietary therapy and treatment
More informationPegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria first line
May 2016 Horizon Scanning Research & Intelligence Centre Pegvaliase for the treatment of hyperphenylalaninaemia in adults with phenylketonuria first line LAY SUMMARY This briefing is based on information
More informationNew treatment options in PKU and future role of dietary treatment
New treatment options in PKU and future role of dietary treatment Michael Staudigl (physician), Katharina Dokoupil (nutritionist), Esther M. Maier (physician, head of department) Dr. von Hauner Children
More informationLarge neutral amino acids in the treatment of PKU: from theory to practice
J Inherit Metab Dis (2010) 33:671 676 DOI 10.1007/s10545-010-9216-1 ADVANCES AND CHALLENGES IN PKU Large neutral amino acids in the treatment of PKU: from theory to practice Francjan J. van Spronsen &
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 96 (2009) 158 163 Contents lists available at ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Minireview Optimizing the
More informationGenetic Counselors role in maternal PKU: Patient and Genetic Counselor perspectives. Master s Thesis. Presented to
Genetic Counselors role in maternal PKU: Patient and Genetic Counselor perspectives Master s Thesis Presented to The Faculty of the Graduate School of Arts and Sciences Brandeis University Department of
More informationOriginal Articles. Pitfalls in the Management of Phenylketonuria in China LL YANG, HQ MAO, WF ZHANG, ZY ZHAO, RL YANG, XL ZHOU, XL HUANG, XW HUANG
HK J Paediatr (new series) 2012;17:143-147 Original Articles Pitfalls in the Management of Phenylketonuria in China LL YANG, HQ MAO, WF ZHANG, ZY ZHAO, RL YANG, XL ZHOU, XL HUANG, XW HUANG Abstract Key
More informationBritish Journal of Nutrition
(2011), 106, 175 182 q The Authors 2011 doi:10.1017/s0007114511000298 Review Article Adjusting diet with sapropterin in phenylketonuria: what factors should be considered? Anita MacDonald 1 *, Kirsten
More informationThe Effect of Phenylalanine Test Frequency on Management of Phenylketonuria (PKU)
DEPARTMENT OF ECONOMICS WORKING PAPER SERIES The Effect of Phenylalanine Test Frequency on Management of Phenylketonuria (PKU) Norman Waitzman Cihan Bilginsoy Claire O. Leonard Sharon L. Ernst Annie Prince
More informationNot intended for UK based media. Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years of age
Your Contact News Release Bettina Frank Phone +49 6151 72-4660 Not intended for UK based media Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in children with PKU below 4 years
More informationUniversity of Groningen. A lifetime with Phenylketonuria Jahja, Rianne
University of Groningen A lifetime with Phenylketonuria Jahja, Rianne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the
More informationMerck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU Below 4 Years of Age
Your Contact News Release Gangolf Schrimpf +49 6151 72-9591 Investor Relations +49 6151 72-3321 July 20, 2015 Merck KGaA, Darmstadt, Germany, Receives EU-Approval to Extend Kuvan Use to Children with PKU
More informationThe What, Why and How of Large Neutral Amino Acids
The What, Why and How of Large Neutral Amino Acids Kathryn Moseley, MS, RD Assistant Professor of Pediatrics USC/Keck School of Medicine LAC+USC Medical Center December 5 th, 2017 The opinions reflected
More informationExtended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: A pilot study
Molecular Genetics and Metabolism 86 (2005) S1 S5 www.elsevier.com/locate/ymgme Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: A pilot study Betina Fiege
More information44. Screening for Phenylketonuria
44. Screening for Phenylketonuria Burden of Suffering PKU is an inborn error of phenylalanine metabolism that occurs in 1 of every 12,000 births in North America. 1,2 In the absence of treatment during
More informationPhenylketonuria: a review of current and future treatments
Editor s note: Rare Diseases Column is chaired by Dr. Zhanhe Wu from The Children s Hospital at Westmead, Australia, featuring articles related to rare diseases mostly genetic based, presented in early
More informationSapropterin dihydrochloride treatment in Turkish hyperphenylalaninemic patients under age four
The Turkish Journal of Pediatrics 2015; 57: 213-218 Original Sapropterin dihydrochloride treatment in Turkish hyperphenylalaninemic patients under age four Özlem Ünal 1, Hülya Gökmen-Özel 2, Turgay Coşkun
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationThe neonatal tetrahydrobiopterin loading test in phenylketonuria: what is the predictive value?
Anjema et al. Orphanet Journal of Rare Diseases (2016) 11:10 DOI 10.1186/s13023-016-0394-2 RESEARCH Open Access The neonatal tetrahydrobiopterin loading test in phenylketonuria: what is the predictive
More informationBest Practices for Optimal Management of Patients With Phenylketonuria Across the Lifespan: How Should the Latest Evidence Inform Our Practice?
Best Practices for Optimal Management of Patients With Phenylketonuria Across the Lifespan: How Should the Latest Evidence Inform Our Practice? Nicola Longo, MD, PhD Professor and Chief Medical Genetics/Pediatrics
More informationCLINICAL NUTRITION. Body mass index in adult patients with diet-treated phenylketonuria
CLINICAL NUTRITION Body mass index in adult patients with diet-treated phenylketonuria L. V. Robertson,* N. McStravick, S. Ripley, E. Weetch, S. Donald, S. Adam,** A. Micciche, S. Boocock,* & A. MacDonald
More informationNew Drug Evaluation: Pegvaliase-pqpz injection, subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationPhenylalanine hydroxylase (PAH)
595862CANXXX10.1177/1941406415595862Infant, Child, & Adolescent NutritionInfant, Child, & Adolescent Nutrition research-articlexxxx ICAN: Infant, Child, & Adolescent Nutrition October 2015 Evidence Based
More informationPKU, KUVAN, and Your Child Making smart choices for PKU treatment
PKU, KUVAN, and Your Child Making smart choices for PKU treatment An educational brochure brought to you by BioMarin Pharmaceutical Inc. + = Low Low- diet Indication KUVAN (sapropterin dihydrochloride)
More informationUvA-DARE (Digital Academic Repository) Phenylketonuria: impact and implications ten Hoedt, A.E. Link to publication
UvA-DARE (Digital Academic Repository) Phenylketonuria: impact and implications ten Hoedt, A.E. Link to publication Citation for published version (APA): ten Hoedt, A. E. (2012). Phenylketonuria: impact
More informationPKU TEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ DESIGNED AND ADAPTED BY THE DIETITIANS GROUP
TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED AND ENDORSED BY ASIEM FOR USE IN ANZ Australasian Society for Inborn Errors of Metabolism DESIGNED AND ADAPTED BY THE DIETITIANS GROUP PKU British
More informationLong-term treatment of phenylketonuria with a new medical food containing large neutral amino acids
OPEN European Journal of Clinical Nutrition (2017) 71, 51 55 www.nature.com/ejcn ORIGINAL ARTICLE Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids D Concolino
More informationPKU PKU. Phenylketonuria TEMPLE. Information for families following Information for families after a positive newborn screening
PKU Phenylketonuria PKU Information for families following newborn a positive screening newborn screening Information for families after a positive newborn screening Information for families after a positive
More informationAnnual Conference. 34th. The Rendezvous Hotel Skipton, Yorkshire. Welcome to. Programme Information & Abstracts
Welcome to 34th Annual Conference 2007 Programme Information & Abstracts The Rendezvous Hotel Skipton, Yorkshire The National Society for Phenylketonuria (United Kingdom) Ltd. NSPKU, PO Box 26642, London
More informationNutritional management of phenylalanine hydroxylase (PAH) deficiency in pediatric patients in Canada: a survey of dietitians current practices
Yuskiv et al. Orphanet Journal of Rare Diseases (2019) 14:7 https://doi.org/10.1186/s13023-018-0978-0 RESEARCH Open Access Nutritional management of phenylalanine hydroxylase (PAH) deficiency in pediatric
More informationNIH Public Access Author Manuscript Curr Dir Psychol Sci. Author manuscript; available in PMC 2010 February 1.
NIH Public Access Author Manuscript Published in final edited form as: Curr Dir Psychol Sci. 2009 February 1; 18(1): 48 52. doi:10.1111/j.1467-8721.2009.01604.x. Phenylketonuria in Children and Mothers:
More informationEfficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria
DOI 10.1007/s10545-012-9464-3 ORIGINAL ARTICLE Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria Oriane Leuret & Magalie Barth & Alice Kuster & Didier Eyer & Loïc
More informationNeurocognitive and Behavioral Issues in PKU
Neurocognitive and Behavioral Issues in PKU Susan Waisbren, PhD Associate Professor of Psychology Harvard Medical School Children s Hospital Boston Boston, Massachusetts Content developed in conjunction
More informationA Pilot Study on the Attitudes of Management Practices in Adults with PKU
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Public Access Theses and Dissertations from the College of Education and Human Sciences Education and Human Sciences, College
More informationPHENYLKETONURIA. Debbie Galo
PHENYLKETONURIA Debbie Galo What it is PKU? 1934 Metabolic disorder (chromosome 12) Autosomal recessive Deficiency of enzyme Phenylalanine Hydroxylase (PAH) Cannot convert phenylalanine to tyrosine More
More informationClinical Commissioning Policy: The use of Sapropterin in children with Phenylketonuria
Clinical Commissioning Policy: The use of Sapropterin in children with Phenylketonuria Reference: E06/P/a NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and Information
More informationManagement of Phenylketonuria. A consensus document for the diagnosis and management of children, adolescents and adults with phenylketonuria (PKU)
Management of Phenylketonuria A consensus document for the diagnosis and management of children, adolescents and adults with phenylketonuria (PKU) July 2014 Management of PKU First edition September 1998
More information1 Cognitive, Psychological and Behavioral Assessment Based Evidence
1 Cognitive, Psychological and Behavioral Assessment Based Evidence Preface Current medical evidence has led experts on PKU to suspect that current therapy for PKU may leave individuals with an increased
More informationMolecular Genetics and Metabolism
Molecular Genetics and Metabolism 106 (2012) 264 268 Contents lists available at SciVerse ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Positive effect
More informationTEMPLE. Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP. British Inherited Metabolic Diseases Group
TEMPLE Tools Enabling Metabolic Parents LEarning ADAPTED BY THE DIETITIANS GROUP British Inherited Metabolic Diseases Group BASED ON THE ORIGINAL TEMPLE WRITTEN BY BURGARD AND WENDEL PKU Information for
More informationESPEN Congress Madrid 2018
ESPEN Congress Madrid 2018 Inborn Errors Of Metabolism Phenylketonuria A. Macdonald (UK) Approach to Dietary Management of PKU Conflicts of interest Anita MacDonald has received research funding and honoraria
More informationNeuropsychological Development in Children with Early and. Continuously Treated Phenylketonuria: Association with. Biochemical Markers
Neuropsychological Development in Children with Early and Continuously Treated Phenylketonuria: Association with Biochemical Markers Rachael Rebecca Sharman B.A., BPsych(Hons) A thesis submitted in accordance
More informationScreening for Phenylketonuria: A Literature Update for the U.S. Preventive Services Task Force
Screening for Phenylketonuria: A Literature Update for the U.S. Preventive Services Task Force Prepared by: Iris Mabry-Hernandez, MD, MPH Tracy Wolff, MD, MPH Kathy Green, MD, MPH Corresponding Author:
More informationSuboptimal provision of medications and dietary products for phenylketonuria in Malta
Suboptimal provision of medications and dietary products for phenylketonuria in Malta Abstract In Malta phenylketonuria (PKU) is mostly due to dihydropteridine reductase (DHPR) deficiency rather than phenylalanine
More informationScreening for Congenital Hypothyroidism in Newborns: A Literature Update for the U.S. Preventive Services Task Force
Screening for Congenital Hypothyroidism in Newborns: A Literature Update for the U.S. Preventive Services Task Force Prepared by: David Meyers, M.D. Stephen Haering, M.D., M.P.H. Agency for Healthcare
More informationMaple Syrup Urine Disease (MSUD) Kiersten Anderson Dietetic Intern February 11, 2011
Maple Syrup Urine Disease (MSUD) Kiersten Anderson Dietetic Intern February 11, 2011 Maple Syrup Urine Disease, defined: A metabolic disorder characterized by a deficiency of branched-chain α-ketoacid
More informationSelf-rated Mental Health Status (G1) Behavioral Risk Factors Surveillance System (BRFSS).
Indicator: Self-rated Mental Health Status (G1) Domain: Sub-domain: Demographic group: Data resource: Data availability: Numerator: Denominator: Measures of frequency: Period of case definition: Significance:
More informationClinical Commissioning Policy: The Use of Sapropterin in Children
Clinical Commissioning Policy: The Use of Sapropterin in Children Reference: NHS England xxx/x/x 1 Clinical Commissioning Policy: The Use of Sapropterin in Children Prepared by NHS England Specialised
More informationLong-term Follow-up and Outcome of Phenylketonuria Patients on Sapropterin: A Retrospective Study. abstract ARTICLE
ARTICLE Long-term Follow-up and Outcome of Phenylketonuria Patients on Sapropterin: A Retrospective Study AUTHORS: Stefanie Keil, MD, a,b Karen Anjema, MD, c Francjan J. van Spronsen, MD, PhD, c Nilo Lambruschini,
More informationEmotional Outcome of Adolescents and Young Adults With Early and Continuously Treated Phenylketonuria
Journal of Pediatric Psychology, Vol. 26, No. 8, 2001, pp. 477 484 Emotional Outcome of Adolescents and Young Adults With Early and Continuously Treated Phenylketonuria Jill E. Sullivan, PhD University
More informationAmal Alamri. Phenylketonuria
Amal Alamri Phenylketonuria Norwegian doctor Asbjørn Følling (left) discovered phenylpyrouvica (later termed phenylketonuria) in 1934 upon discovering that ten mentally retarded patients had phenylpyruvic
More informationDisclosure. I have no disclosures to mention
Disclosure I have no disclosures to mention Liberalization of the Dietary Restrictions for PKU Patients: Large Neutral Amino Acids (LNAA) Supplementation in PKU Mice Dr. Eddy A. van der Zee, University
More informationSupporting improved nutrition for appropriate growth and improved long-term health outcomes
Supporting improved nutrition for appropriate growth and improved long-term health outcomes ZTC831/07/2015 The first 1000 days are a critical period for growth and development Achieving optimal nutrition
More informationHA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up
HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up Dr. Josephine Chong Clinical Professional Consultant Centre of Inborn Errors
More informationDevelopment of the US English version of the phenylketonuria quality of life (PKU-QOL) questionnaire
Jurecki et al. Health and Quality of Life Outcomes (2017) 15:46 DOI 10.1186/s12955-017-0620-1 RESEARCH Open Access Development of the US English version of the phenylketonuria quality of life (PKU-QOL)
More informationEARLY TREATMENT OF PHENYLKETONURIA AND DEVELOPMENTAL ABILITIES
FACULDADE DE ODONTOLOGIA DE BAURU UNIVERSIDADE DE SÃO PAULO DEPARTAMENTO DE FONOAUDIOLOGIA EARLY TREATMENT OF PHENYLKETONURIA AND DEVELOPMENTAL ABILITIES SLP Silva, Greyce Kelly Phd Lamônica, Dionísia
More informationJoGN N PR~UCIPLES & PRACTICE
JoGN N PR~UCIPLES & PRACTICE Maternal Phenylketonuria: A New Cause for Concern Robin B. Kirby, RNC, MSN, CRNP = The start of newborn screening for phenylketonuria (PKU) during the early 1970s has given
More informationCURRICULUM VITAE ET STUDIORUM
CURRICULUM VITAE ET STUDIORUM Francesco Porta, MD Personal data Born: July 2 nd,1980, Mondovì (Cuneo), Italy Work address: Department of Pediatrics, University of Torino Piazza Polonia 94, 10126 Torino
More informationMSUD is a complex condition. Consider Vitaflo s comprehensive range. Making life easier, everyday.
MSUD is a complex condition Consider Vitaflo s comprehensive range. Making life easier, everyday.. At Vitaflo we appreciate the dietary management of MSUD is complex. Vitaflo offers a comprehensive range
More informationIMPORTANCE OF ALPHA-LACTALBUMIN IN INFANT NUTRITION
IMPORTANCE OF ALPHA-LACTALBUMIN IN INFANT NUTRITION By Dr Dan Alaro Learning Objective Describe the roles of α-lactalbumin as an important nutrients for infants. Protein Composition : Human milk The whey-to
More informationPhenylketonuria (PKU) the Biochemical Basis. Biol 405 Molecular Medicine
Phenylketonuria (PKU) the Biochemical Basis Biol 405 Molecular Medicine PKU a history In 1934 Følling identified a clinical condition - imbecillitas phenylpyruvica. Mental retardation associated with this
More informationIndication criteria for disease: Phenylketonuria (PKU) [PAH]
deutsche gesellschaft für humangenetik e.v. Indication Criteria for Genetic Testing Evaluation of validity and clinical utility german society of human genetics www.gfhev.de Indication criteria for disease:
More informationPKU. and the brain. How PKU affects the brain. Is there a relationship between PKU and ADHD? Assessments in metabolic clinics.
Learning disabilities and academic performance How PKU affects the brain PKU and the brain Assessments in metabolic clinics Physical evidence Is there a relationship between PKU and ADHD? Current and promising
More informationAMERICAN ACADEMY OF PEDIATRICS. New Developments in Hyperphenylalaninemia. Committee on Nutrition
AMERICAN ACADEMY OF PEDIATRICS Committee on Nutrition New Developments in Hyperphenylalaninemia In recent years it has become apparent that hyperphenylalaninemia in newborn infants may be caused by a variety
More informationAn introduction to Phenylketonuria (PKU)
An introduction to Phenylketonuria (PKU) What is PKU? Phenylketonuria (sounds like feen-il-ke-ton-u-re-ah) or PKU for short PKU is a manageable condition which affects the way the body uses protein. Children
More informationCitation for published version (APA): Rijn, M. V. (2007). Dietary Treatment in PKU from experience to evidence s.n.
University of Groningen Dietary Treatment in PKU from experience to evidence Rijn, Margaretha van IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationContraindications to breast feeding. Dr. Ahmed Isam
Contraindications to breast feeding Dr. Ahmed Isam When should a mother avoid breastfeeding? Health professionals agree that human milk provides the most complete form of nutrition for infants, including
More informationChapter 17: Disorders of Amino Acid Metabolism, Organic Acidaemias and Urea Cycle Disorders
Chapter 17: Disorders of Amino Acid Metabolism, Organic Acidaemias and Urea Cycle Disorders 1. Garrod AE The incidence of alkaptonuria: a study in chemical individuality. Lancet, 1902, 2 1616 20. 2. Garrod
More informationUniversity of Groningen. A lifetime with Phenylketonuria Jahja, Rianne
University of Groningen A lifetime with Phenylketonuria Jahja, Rianne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the
More informationSummary 1. Comparative effectiveness of sapropterin dihydrochloride
Cost-effectiveness of sapropterin dihydrochloride (Kuvan ) for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown
More informationTable of Contents Preface...1 What is PKU?...2 Where does PKU come from?...3 How is PKU Treated?...4 Controlling Blood Phe *...5 Phenyl-Free How
New Parents' Table of Contents Preface...1 What is PKU?...2 Where does PKU come from?...3 How is PKU Treated?...4 Controlling Blood Phe *...5 Phenyl-Free 1...6 How to Prepare Phenyl-Free 1...7 The PKU
More informationQuality of Life (QoL) assessment in a cohort of patients with Phenylketonuria
Cazzorla et al. BMC Public Health 2014, 14:1243 RESEARCH ARTICLE Open Access Quality of Life (QoL) assessment in a cohort of patients with Phenylketonuria Chiara Cazzorla 1, Luca Cegolon 2,3, Alessandro
More informationAustralasian consensus guidelines for the management of maternal phenylketonuria (PKU).
Australasian consensus guidelines for the management of maternal phenylketonuria (PKU). Inwood AC 1, *, Mordaunt DA 2, Peters J 3 Elliott A 1, Westbrook M 4, Tchan MC 4 Akroyd R 5, Sivakumar P 6, Fletcher
More informationParenting a child with phenylketonuria or galactosemia: implications for health-related quality of life
J Inherit Metab Dis (2011) 34:391 398 DOI 10.1007/s10545-010-9267-3 GALACTOSEMIA Parenting a child with phenylketonuria or galactosemia: implications for health-related quality of life Amber E. ten Hoedt
More informationPhenylalanine. in cases of hyperphenylalaninemia and tetrahydrobiopterin deficiency
Evolving Methods for the Measurement of Phenylalanine A vital diagnostic marker and indicator for follow-up in cases of hyperphenylalaninemia and tetrahydrobiopterin deficiency Dr. Zoltan Lukacs Department
More informationRecommendations for the nutrition management of phenylalanine hydroxylase deficiency
American College of Medical Genetics and Genomics Systematic Review Open Recommendations for the nutrition management of phenylalanine hydroxylase deficiency Rani H. Singh, PhD, RD 1, Fran Rohr, MS, RD
More informationThe outcome of PKU: the relevance of neuroimaging and neurophysiological examinations. Vincenzo Leuzzi
Department of Pediatrics and Pediatric Neurology and Psychiatry The outcome of PKU: the relevance of neuroimaging and neurophysiological examinations Vincenzo Leuzzi vincenzo.leuzzi@uniroma1.it The aims
More informationPhone: Fax:
Cognitive performance in adolescent phenylketonuria patients on relaxed diet supplemented with.phenylalanine-free amino acid tablets versus strict dietary therapy by Jente Andresen, M.Sc., Kirsten Ahring,
More informationVitamin D during pregnancy and breastfeeding
Vitamin D during pregnancy and breastfeeding Getting the right nutrients and eating well when you re pregnant or breastfeeding is important for your baby s growth and development. Vitamin D helps you to
More information